Literature DB >> 18280509

Best practice policy statement on urologic surgery antimicrobial prophylaxis.

J Stuart Wolf1, Carol J Bennett, Roger R Dmochowski, Brent K Hollenbeck, Margaret S Pearle, Anthony J Schaeffer.   

Abstract

PURPOSE: Antimicrobial prophylaxis is the periprocedural systemic administration of an antimicrobial agent intended to reduce the risk of postprocedural local and systemic infections. The AUA convened a BPP Panel to formulate recommendations on the use of antimicrobial prophylaxis during urologic surgery.
MATERIALS AND METHODS: Recommendations are based on a review of the literature and the Panel members' expert opinions.
RESULTS: The potential benefit of antimicrobial prophylaxis is determined by patient factors, procedure factors, and the potential morbidity of infection. Antimicrobial prophylaxis is recommended only when the potential benefit outweighs the risks and anticipated costs (including expense of agent and administration, risk of allergic reactions or other adverse effects, and induction of bacterial resistance). The prophylactic agent should be effective against organisms characteristic of the operative site. Cost, convenience, and safety of the agent also should be considered. The duration of antimicrobial prophylaxis should extend throughout the period when bacterial invasion is facilitated and/or likely to establish an infection. Prophylaxis should begin within 60 minutes of the surgical incision (120 minutes for intravenous fluoroquinolines and vancomycin) and generally should be discontinued within 24 hours. The AHA no longer recommends antimicrobial prophylaxis for genitourinary surgery solely to prevent infectious endocarditis. Justifications and recommendations for specific antimicrobial prophylactic regimens for specific categories of urologic procedures are provided.
CONCLUSIONS: The recommendations provided in this document, including specific indications and agents enumerated in the Tables, can assist urologists in the appropriate use of periprocedural antimicrobial prophylaxis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18280509     DOI: 10.1016/j.juro.2008.01.068

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  161 in total

Review 1.  Asymptomatic bacteriuria: when the treatment is worse than the disease.

Authors:  Barbara W Trautner
Journal:  Nat Rev Urol       Date:  2011-12-06       Impact factor: 14.432

2.  Infection: prostate biopsy-infection and prior fluoroquinolone exposure.

Authors:  Michael A Liss
Journal:  Nat Rev Urol       Date:  2011-10-11       Impact factor: 14.432

Review 3.  Risk factors for sepsis after percutaneous renal stone surgery.

Authors:  Evgeniy I Kreydin; Brian H Eisner
Journal:  Nat Rev Urol       Date:  2013-09-03       Impact factor: 14.432

4.  Chemoprophylaxis during transrectal prostate needle biopsy: critical analysis through randomized clinical trial.

Authors:  Ahmed M Elshal; Ahmed M Atwa; Ahmed R El-Nahas; Mohamed A El-Ghar; Asaad Gaber; Essam Elsawy; Abdelwahab Hashem; Yasser Farag; Hashim Farg; Ali Elsorougy; Mohamed Fouda; Hossam Nabeeh; Ahmed Mosbah
Journal:  World J Urol       Date:  2018-05-07       Impact factor: 4.226

5.  Penile implant infections: prevention and treatment.

Authors:  John J Mulcahy
Journal:  Curr Urol Rep       Date:  2008-11       Impact factor: 3.092

6.  Assessment of antibiotic prophylaxis prescribing patterns for TURP: A need for Canadian guidelines?

Authors:  Keith A Lawson; Jan K Rudzinski; Ingrid Vicas; Kevin V Carlson
Journal:  Can Urol Assoc J       Date:  2013 Jul-Aug       Impact factor: 1.862

Review 7.  Prostate biopsy for the interventional radiologist.

Authors:  Cheng William Hong; Hayet Amalou; Sheng Xu; Baris Turkbey; Pingkun Yan; Jochen Kruecker; Peter A Pinto; Peter L Choyke; Bradford J Wood
Journal:  J Vasc Interv Radiol       Date:  2014-02-26       Impact factor: 3.464

8.  Pharmacologically induced erect penile length and stretched penile length are both good predictors of post-inflatable prosthesis penile length.

Authors:  E C Osterberg; A Maganty; R Ramasamy; J F Eid
Journal:  Int J Impot Res       Date:  2014-01-16       Impact factor: 2.896

Review 9.  Performance Measurement and Quality Improvement Initiatives for Bladder Cancer Care.

Authors:  Benjamin T Ristau; Marc C Smaldone
Journal:  Curr Urol Rep       Date:  2018-10-24       Impact factor: 3.092

10.  Loss of function dysbiosis associated with antibiotics and high fat, high sugar diet.

Authors:  Aaron W Miller; Teri Orr; Denise Dearing; Manoj Monga
Journal:  ISME J       Date:  2019-01-30       Impact factor: 10.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.